Gilead wins patent battle with US government over HIV PrEP drugs
Pharmaceutical Technology
MAY 10, 2023
While the government said that Gilead secured its PrEP approvals only after CDC’s research on the topic, the company stated that there already were published materials on the potential use of antiretroviral therapies as PrEP prior to this. Gilead markets both Truvada and its successor Descovy.
Let's personalize your content